Earlier this week, we had a great conversation with CMO of psychedelic company Mydecine Innovations Group (NEO: MYCO) Dr. Rakesh Jetly to talk about his history and experience in treating veterans with PTSD. In the second part of this interview, we get more in depth on the Phase 2 Clinical Trials soon to be underway at Mydecine using psilocybin assisted psychotherapy, and the narrative Dr. Jetly wants investors to know about the future of psychedelic treatment in a host of mental disorders.
A quick recap from before: Dr. Jetly, who has over 30 years of experience working with the Canadian military, began working in clinics to treat post traumatic stress disorder in veterans in 2000, and saw little to no response to the standard evidence-based treatments available at the time. Starting around 2010, he began looking at novel approaches to treating the disorder. Be sure to see the whole episode here.
Here’s some highlights from part 2 of the interview ..
We are The Dales Report.
Check out our website: https://thedalesreport.com/
Subscribe to our channel at https://article.thedalesreport.com/youtube
Connect with us on our social media handles: